Clinical Trial: Long Term Prediction of MASH-related HCC Risk by Proteomics

U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332611) titled 'Long Term Prediction of MASH-related HCC Risk by Proteomics' on Dec. 30, 2025.

Brief Summary: MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), affects over 25% of the global population and is increasingly associated with obesity and type 2 diabetes. Metabolic Dysfunction-Associated Steatohepatitis (MASH), a progressive form of MASLD, can lead to cirrhosis and hepatocellular carcinoma (HCC). MASH is now responsible for up to 35% of HCC cases worldwide, including in non-cirrhotic patients who fall outside routine HCC screening recommendations. Unfortunately, no predictive biomarkers of malignant transformation are cur...